Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa

Haematologica

Volumn 90, Issue 11, 2005, Pages 1578-1580

  Ferreri, Andrés J M ^a   Ponzoni, Maurilio ^a   Martinelli, Giovanni ^b   Muti, Giuliana ^c   Guidoboni, Massimo ^d   Dolcetti, Riccardo ^d   Doglioni, Claudio ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

MALT lymphoma; Ocular adnexal lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXYCYCLINE; PREDNISONE; RECOMBINANT INTERFERON; RITUXIMAB; VINCRISTINE;

ADNEXA DISEASE; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; FOLLOW UP; HUMAN; LYMPHOMA; MALE; TREATMENT FAILURE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; EYE NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 27844576115     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Concord A, Martinelli G, Thieblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003;102:2741-5.
2. Zucca E, Conconi A, Fedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoia tissue. International Extranodal Lymphoma Study Group. Blood 2003;101:2489-95.
3. Nuckel H, Meller D, Steuhl KP, Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol 2004;73:258-62.
4. Sullivan TJ, Grimes D, Bunce I. Monoclonal antibody treat ment of orbital lymphoma. Ophthal Plast Reconstr Surg 2004;20:103-6.
5. Raderer M, Jager G, Brugger S, Puspok A, Fiebiger W, Drach J, et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003;65:306-10.
6. Zubrod CG, Scheidermann MA, Frei E. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 1960;11:7-33.
7. Zinzani PL, Alinari L, Stefoni V, Loffredo A, Pichierri P, Polito E. Rituximab in primary conjunctiva lymphoma. Leuk Res 2005;29:107-8.
8. Esmaeli B, Murray JL, Ahmadi MA, Naderi A, Singh S, Romaguera J, et al. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit. Arch Ophthalmol 2002;120:1225-7.
9. Martinelli G, Laszlo D, Ferreri AJ, Pruned G, Ponzoni M, Concord A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979-83.